Exemestane

Generic Name
Exemestane
Brand Names
Aromasin
Drug Type
Small Molecule
Chemical Formula
C20H24O2
CAS Number
107868-30-4
Unique Ingredient Identifier
NY22HMQ4BX
Background

Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.

Indication

For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.

Associated Conditions
Stage I Breast Cancer, Refractory, advanced Breast cancer
Associated Therapies
-

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

First Posted Date
2020-03-09
Last Posted Date
2024-06-03
Lead Sponsor
MedSIR
Target Recruit Count
69
Registration Number
NCT04300790
Locations
🇪🇸

Hospital General Universitario de Alicante, Alicante, Spain

🇪🇸

Hospital Universitario de Leon, León, Spain

🇪🇸

Hospital Beata María Ana, Madrid, Spain

and more 16 locations

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

First Posted Date
2019-10-16
Last Posted Date
2024-05-07
Lead Sponsor
Johns Hopkins University
Target Recruit Count
30
Registration Number
NCT04129216
Locations
🇺🇸

Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

First Posted Date
2019-08-16
Last Posted Date
2024-10-22
Lead Sponsor
Sanofi
Target Recruit Count
367
Registration Number
NCT04059484
Locations
🇺🇦

Investigational Site Number : 8040001, Kryvyi Rih, Ukraine

🇬🇷

Investigational Site Number : 3000004, Thessaloniki, Greece

🇧🇷

Hospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil

and more 106 locations

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

First Posted Date
2018-10-01
Last Posted Date
2023-11-15
Lead Sponsor
Emory University
Target Recruit Count
38
Registration Number
NCT03691493
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

🇺🇸

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States

and more 7 locations

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

First Posted Date
2018-09-06
Last Posted Date
2024-07-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
103
Registration Number
NCT03659136
Locations
🇧🇪

Brussels - UNIV Saint-Luc, Bruxelles, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

🇺🇸

Cancer Treatment Centers of America at Western Regional Medical Center, Goodyear, Arizona, United States

and more 51 locations

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

First Posted Date
2018-06-14
Last Posted Date
2023-07-07
Lead Sponsor
German Breast Group
Target Recruit Count
56
Registration Number
NCT03555877
Locations
🇩🇪

Studienzentrum Onkologie Ravensburg, Ravensburg, Germany

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

First Posted Date
2018-05-29
Last Posted Date
2021-07-09
Lead Sponsor
Taizhou EOC Pharma Co., Ltd.
Target Recruit Count
375
Registration Number
NCT03538171
Locations
🇨🇳

Cancer Hospital Chinese Academy Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath